ORGO
Organogenesis Holdings Inc.NASDAQHealthcare$2.24-3.03%ClosedMarket Cap: $288.2M
As of 2026-04-06
Valuation
P/E (TTM)
7.78
PEG
0.00
P/B
0.66
P/S
0.51
EV/EBITDA
4.23
DCF Value
$2.52
FCF Yield
-8.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.4%
Operating Margin
8.3%
Net Margin
6.6%
ROE
9.6%
ROA
6.2%
ROIC
7.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $225.6M | 74.8% | $65.2M | $43.7M | $0.27 | — |
| FY 2025 | $564.2M | 73.6% | $56.4M | $37.0M | $0.15 | — |
| Q3 2025 | $150.9M | 76.0% | $20.7M | $21.6M | $0.11 | — |
| Q2 2025 | $100.8M | 72.6% | $-12.6M | $-9.4M | $-0.10 | — |
| Q1 2025 | $86.7M | 72.6% | $-26.7M | $-18.8M | $-0.17 | — |
| Q4 2024 | $126.7M | 75.5% | $10.2M | $7.7M | $0.04 | — |
| FY 2024 | $482.0M | 76.0% | $-1.3M | $861.0K | $-0.01 | — |
| Q3 2024 | $115.2M | 76.7% | $6.2M | $12.3M | $0.09 | — |
| Q2 2024 | $130.2M | 77.6% | $-13.9M | $-17.0M | $-0.13 | — |
| Q1 2024 | $110.0M | 73.9% | $-3.9M | $-2.1M | $-0.02 | — |
| Q4 2023 | $99.7M | 72.1% | $-1.3M | $-568.0K | $-0.00 | — |
| FY 2023 | $433.1M | 75.4% | $12.5M | $4.9M | $0.04 | — |